Tarra Shingler

Tarra Shingler has an extensive work experience in the pharmaceutical and healthcare industry. Tarra currently holds the position of Chief Commercial Officer (CCO) at StudyKIK, a clinical trial recruitment and retention company. Prior to this, they served as the Senior Vice President of Global Business Solutions at StudyKIK before it was acquired by Syneos Health. Tarra has also worked as the Vice President of Business Development in North America at Synteract, which was later acquired by Syneos Health. At ERT, a global clinical endpoint technology-focused vendor, they held the role of Senior Director of Strategic Partnerships, where they focused on establishing partnerships with global Contract Research Organizations (CROs). Tarra has also worked as a Clinical Project Manager at Mylan and held various positions at Endo Pharmaceuticals Inc., including Associate Director of Clinical Outsourcing and Manager of Clinical Outsourcing. Earlier in their career, they worked at Solstice Neurosciences, Pharmion (now Celegene Corporation), and Shire Pharmaceuticals Inc. (now Takeda), where they gained experience in clinical development, project management, and medical affairs activities. Overall, Tarra Shingler has over seventeen years of experience and has contributed to various aspects of drug development, clinical operations, strategic partnerships, and business development.

Tarra Shingler's education history includes obtaining a Master of Science in Clinical Research (MSHS) from The George Washington University, where they studied from 2002 to 2004. Prior to that, they completed their Bachelor of Science degree in Physiology at Penn State University from 1996 to 2000.

In addition to their formal education, Tarra Shingler has also earned certifications in various areas. Tarra obtained the Rare Disease Institute certification from Synteract in July 2020. Previously, in March 2020, they completed the MMachine MMasterclass certification offered by MMasters Corporation.